JP6061344B2 - 大腸癌の診断 - Google Patents
大腸癌の診断 Download PDFInfo
- Publication number
- JP6061344B2 JP6061344B2 JP2013518909A JP2013518909A JP6061344B2 JP 6061344 B2 JP6061344 B2 JP 6061344B2 JP 2013518909 A JP2013518909 A JP 2013518909A JP 2013518909 A JP2013518909 A JP 2013518909A JP 6061344 B2 JP6061344 B2 JP 6061344B2
- Authority
- JP
- Japan
- Prior art keywords
- m2pk
- igfbp2
- dkk
- epcam
- mac2bp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010009944 Colon cancer Diseases 0.000 title claims description 88
- 208000001333 Colorectal Neoplasms Diseases 0.000 title claims description 76
- 238000003745 diagnosis Methods 0.000 title description 13
- 239000000090 biomarker Substances 0.000 claims description 164
- 238000000034 method Methods 0.000 claims description 127
- 102100037985 Dickkopf-related protein 3 Human genes 0.000 claims description 78
- 101710099550 Dickkopf-related protein 3 Proteins 0.000 claims description 77
- -1 M2PK Proteins 0.000 claims description 71
- 108090001007 Interleukin-8 Proteins 0.000 claims description 70
- 108090000176 Interleukin-13 Proteins 0.000 claims description 62
- 102000003816 Interleukin-13 Human genes 0.000 claims description 62
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims description 52
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims description 52
- 102000004890 Interleukin-8 Human genes 0.000 claims description 32
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 claims description 29
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 claims description 29
- 206010028980 Neoplasm Diseases 0.000 claims description 27
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 26
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 26
- 229920001184 polypeptide Polymers 0.000 claims description 25
- 150000001875 compounds Chemical class 0.000 claims description 22
- 102100040510 Galectin-3-binding protein Human genes 0.000 claims description 21
- 230000014509 gene expression Effects 0.000 claims description 21
- 101710197901 Galectin-3-binding protein Proteins 0.000 claims description 20
- 238000001514 detection method Methods 0.000 claims description 20
- 210000002966 serum Anatomy 0.000 claims description 16
- 210000002381 plasma Anatomy 0.000 claims description 14
- 208000029742 colonic neoplasm Diseases 0.000 claims description 13
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 102000040430 polynucleotide Human genes 0.000 claims description 7
- 108091033319 polynucleotide Proteins 0.000 claims description 7
- 239000002157 polynucleotide Substances 0.000 claims description 7
- 238000000338 in vitro Methods 0.000 claims description 5
- 102000013009 Pyruvate Kinase Human genes 0.000 claims description 4
- 108020005115 Pyruvate Kinase Proteins 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 108010055165 Chemokine CCL4 Proteins 0.000 claims description 3
- 108090001005 Interleukin-6 Proteins 0.000 claims description 3
- 102100030417 Matrilysin Human genes 0.000 claims description 3
- 108090000855 Matrilysin Proteins 0.000 claims description 3
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 claims description 3
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 claims description 3
- 210000001772 blood platelet Anatomy 0.000 claims description 3
- 210000003593 megakaryocyte Anatomy 0.000 claims description 3
- 210000002700 urine Anatomy 0.000 claims description 3
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 claims description 2
- 102100026802 72 kDa type IV collagenase Human genes 0.000 claims description 2
- 101710151806 72 kDa type IV collagenase Proteins 0.000 claims description 2
- 102100038778 Amphiregulin Human genes 0.000 claims description 2
- 108010033760 Amphiregulin Proteins 0.000 claims description 2
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims description 2
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 2
- 102100036150 C-X-C motif chemokine 5 Human genes 0.000 claims description 2
- 102000001326 Chemokine CCL4 Human genes 0.000 claims description 2
- 101000947186 Homo sapiens C-X-C motif chemokine 5 Proteins 0.000 claims description 2
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 claims description 2
- 101000742599 Homo sapiens Vascular endothelial growth factor D Proteins 0.000 claims description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 2
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims description 2
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 claims description 2
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 claims description 2
- 102100037850 Interferon gamma Human genes 0.000 claims description 2
- 108010074328 Interferon-gamma Proteins 0.000 claims description 2
- 102000003814 Interleukin-10 Human genes 0.000 claims description 2
- 108090000174 Interleukin-10 Proteins 0.000 claims description 2
- 108090000978 Interleukin-4 Proteins 0.000 claims description 2
- 102000004388 Interleukin-4 Human genes 0.000 claims description 2
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims description 2
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 claims description 2
- 102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 claims description 2
- 102100030416 Stromelysin-1 Human genes 0.000 claims description 2
- 101710108790 Stromelysin-1 Proteins 0.000 claims description 2
- 108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 claims description 2
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 claims description 2
- 102100038234 Vascular endothelial growth factor D Human genes 0.000 claims description 2
- 101001044940 Homo sapiens Insulin-like growth factor-binding protein 2 Proteins 0.000 claims 88
- 102100022710 Insulin-like growth factor-binding protein 2 Human genes 0.000 claims 88
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 claims 1
- 102000005353 Tissue Inhibitor of Metalloproteinase-1 Human genes 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 description 46
- 239000000523 sample Substances 0.000 description 39
- 102000004372 Insulin-like growth factor binding protein 2 Human genes 0.000 description 28
- 108090000964 Insulin-like growth factor binding protein 2 Proteins 0.000 description 28
- 238000004458 analytical method Methods 0.000 description 23
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 21
- 229940096397 interleukin-8 Drugs 0.000 description 21
- 201000011510 cancer Diseases 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 19
- 238000012360 testing method Methods 0.000 description 19
- 101150084967 EPCAM gene Proteins 0.000 description 14
- 238000002790 cross-validation Methods 0.000 description 12
- 108020004707 nucleic acids Proteins 0.000 description 12
- 102000039446 nucleic acids Human genes 0.000 description 12
- 150000007523 nucleic acids Chemical class 0.000 description 12
- 238000002405 diagnostic procedure Methods 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 238000004422 calculation algorithm Methods 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 8
- 238000012216 screening Methods 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 206010061818 Disease progression Diseases 0.000 description 5
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000005750 disease progression Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 239000013610 patient sample Substances 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 238000002052 colonoscopy Methods 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 238000000491 multivariate analysis Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108091058560 IL8 Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000002591 computed tomography Methods 0.000 description 3
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 238000012417 linear regression Methods 0.000 description 3
- 238000007477 logistic regression Methods 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 238000002331 protein detection Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000012353 t test Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- ZKRFOXLVOKTUTA-KQYNXXCUSA-N 9-(5-phosphoribofuranosyl)-6-mercaptopurine Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=S)=C2N=C1 ZKRFOXLVOKTUTA-KQYNXXCUSA-N 0.000 description 2
- 101000815628 Homo sapiens Regulatory-associated protein of mTOR Proteins 0.000 description 2
- 101000652747 Homo sapiens Target of rapamycin complex 2 subunit MAPKAP1 Proteins 0.000 description 2
- 101000648491 Homo sapiens Transportin-1 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 238000012951 Remeasurement Methods 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 102100028748 Transportin-1 Human genes 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 201000002313 intestinal cancer Diseases 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 238000002552 multiple reaction monitoring Methods 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000007637 random forest analysis Methods 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000000611 regression analysis Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000010187 selection method Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000010972 statistical evaluation Methods 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- ZENKESXKWBIZCV-UHFFFAOYSA-N 2,2,4,4-tetrafluoro-1,3-benzodioxin-6-amine Chemical group O1C(F)(F)OC(F)(F)C2=CC(N)=CC=C21 ZENKESXKWBIZCV-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102100021984 C-C motif chemokine 4-like Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 241000160765 Erebia ligea Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000951342 Homo sapiens Dickkopf-related protein 3 Proteins 0.000 description 1
- 101000967904 Homo sapiens Galectin-3-binding protein Proteins 0.000 description 1
- 101000613820 Homo sapiens Osteopontin Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108700012441 IGF2 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 238000012313 Kruskal-Wallis test Methods 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- 101000998548 Yersinia ruckeri Alkaline proteinase inhibitor Proteins 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000020805 dietary restrictions Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002579 sigmoidoscopy Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000000551 statistical hypothesis test Methods 0.000 description 1
- 238000013179 statistical model Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000012706 support-vector machine Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000002366 time-of-flight method Methods 0.000 description 1
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 1
- 239000000107 tumor biomarker Substances 0.000 description 1
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2010903140A AU2010903140A0 (en) | 2010-07-14 | Diagnostic for colorectal cancer | |
| AU2010903140 | 2010-07-14 | ||
| PCT/AU2011/000895 WO2012006681A1 (en) | 2010-07-14 | 2011-07-14 | Diagnostic for colorectal cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013533977A JP2013533977A (ja) | 2013-08-29 |
| JP2013533977A5 JP2013533977A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2014-09-18 |
| JP6061344B2 true JP6061344B2 (ja) | 2017-01-18 |
Family
ID=45468816
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013518909A Active JP6061344B2 (ja) | 2010-07-14 | 2011-07-14 | 大腸癌の診断 |
Country Status (13)
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN2013CN01129A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2010-07-14 | 2015-07-31 | Commw Scient Ind Res Org | |
| US9141756B1 (en) | 2010-07-20 | 2015-09-22 | University Of Southern California | Multi-scale complex systems transdisciplinary analysis of response to therapy |
| EP2671082B1 (en) | 2011-02-02 | 2020-01-15 | Amgen Inc. | Methods and compositons relating to inhibition of igf-1r |
| HUE042708T2 (hu) * | 2012-08-09 | 2019-07-29 | Inst Nat Sante Rech Med | Szívelégtelenség diagnosztika |
| GB201218341D0 (en) * | 2012-10-12 | 2012-11-28 | Orign Sciences Ltd | Diagnostic method |
| JP2017520775A (ja) * | 2014-03-28 | 2017-07-27 | アプライド プロテオミクス，インク． | 結腸直腸腫瘍を検出するためのタンパク質バイオマーカープロファイル |
| SG11201700284UA (en) * | 2014-07-18 | 2017-02-27 | Sanofi Sa | Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer |
| CN106191215B (zh) * | 2015-04-29 | 2020-03-24 | 中国科学院上海生命科学研究院 | 肌肉萎缩相关的蛋白质分子标记Dkk-3的筛选及其应用 |
| CN107847564B (zh) * | 2015-05-12 | 2021-11-09 | 远东超级实验室有限公司 | 鉴定对肿瘤具有直接抑制作用的干扰素的方法及其用途 |
| CN105219844B (zh) * | 2015-06-08 | 2018-12-14 | 华夏京都医疗投资管理有限公司 | 一种筛查十一种疾病的基因标志物组合、试剂盒以及疾病风险预测模型 |
| CN105021828B (zh) * | 2015-07-20 | 2017-07-28 | 上海交通大学医学院附属新华医院 | 通过检测三期结直肠肿瘤患者血清预测肿瘤患者预后 |
| CN105567846A (zh) * | 2016-02-14 | 2016-05-11 | 上海交通大学医学院附属仁济医院 | 检测粪便中细菌dna的试剂盒及其在大肠癌诊断中的应用 |
| JP6984862B2 (ja) * | 2017-03-15 | 2021-12-22 | 国立大学法人金沢大学 | 血中ケモカインをマーカーとして用いた大腸癌の検出 |
| CN107164535A (zh) * | 2017-07-07 | 2017-09-15 | 沈阳宁沪科技有限公司 | 一种无创高通量甲基化结肠癌诊断、研究和治疗方法 |
| CN110540588B (zh) * | 2018-05-28 | 2022-08-23 | 香港中文大学 | 一种基于肿瘤干细胞标志物EpCAM的抗原表位多肽及其应用 |
| CN108957014A (zh) * | 2018-09-27 | 2018-12-07 | 郑州大学第附属医院 | 结直肠癌血清标志物、表达评估方法、试剂盒及应用 |
| JP2022505676A (ja) * | 2018-10-23 | 2022-01-14 | ブラックソーン セラピューティクス インコーポレイテッド | 患者のスクリーニング、診断、及び層別化のためのシステム及び方法 |
| CN109504778B (zh) * | 2019-01-11 | 2021-11-09 | 复旦大学附属中山医院 | 一种基于表观修饰的5hmC多分子标志物及结直肠癌早期诊断模型 |
| CA3131729A1 (en) * | 2019-03-01 | 2020-09-10 | Advanced Marker Discovery S.l. | Protein signature for the diagnosis of colorectal cancer and/or pre-cancerous stage thereof |
| JP7032764B2 (ja) * | 2019-04-03 | 2022-03-09 | 京都府公立大学法人 | 大腸がんの検出方法 |
| JP7300660B2 (ja) * | 2019-04-03 | 2023-06-30 | 京都府公立大学法人 | 大腸がんの検出方法 |
| WO2021097327A1 (en) * | 2019-11-13 | 2021-05-20 | University Of Virginia Patent Foundation | Treatment of clostridium difficile infections |
| EP3835789A1 (en) | 2019-12-13 | 2021-06-16 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Biomarker panel for diagnosing colorectal cancer |
| WO2022130597A1 (ja) * | 2020-12-18 | 2022-06-23 | 国立大学法人東北大学 | 推定装置、推定方法、推定プログラム、生成装置、及び、推定システム |
| CN117355748A (zh) * | 2021-04-20 | 2024-01-05 | 视觉技术生物有限公司 | 结直肠癌的生物标志物 |
| CA3228665A1 (en) * | 2021-08-11 | 2023-02-16 | Trevor Lockett | Method of detecting adenoma |
| WO2023128429A1 (ko) * | 2021-12-31 | 2023-07-06 | 주식회사 이노제닉스 | 대장암 및 진행 선종의 선별 검사 방법 및 그 응용 |
| WO2023128419A1 (ko) * | 2021-12-31 | 2023-07-06 | 주식회사 이노제닉스 | 대장암 및 대장 용종 또는 진행 선종의 선별 방법 및 그 응용 |
| CN114594259B (zh) * | 2022-04-22 | 2022-09-13 | 北京易科拜德科技有限公司 | 一种新型的用于结直肠癌预后预测和诊断的模型及其应用 |
| PL441319A1 (pl) * | 2022-05-31 | 2023-12-04 | Uniwersytet Medyczny Im. Piastów Śląskich We Wrocławiu | Zestaw biomarkerów białkowych i sposób diagnostyki raka jelita grubego in vitro |
| CN119688988A (zh) * | 2024-11-25 | 2025-03-25 | 中国医学科学院肿瘤医院 | Timp1和foxp3作为诊断结直肠癌的生物标志物组合及其应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5925517A (en) | 1993-11-12 | 1999-07-20 | The Public Health Research Institute Of The City Of New York, Inc. | Detectably labeled dual conformation oligonucleotide probes, assays and kits |
| JP2004198419A (ja) * | 2002-12-13 | 2004-07-15 | Bayer Healthcare Llc | Ｔｉｍｐ１を用いた検出方法 |
| US20050014165A1 (en) * | 2003-07-18 | 2005-01-20 | California Pacific Medical Center | Biomarker panel for colorectal cancer |
| US20060094056A1 (en) * | 2003-09-15 | 2006-05-04 | Oklahoma Medical Research Foundation | Method of using cytokine assays to diagnose treat, and evaluate inflammatory and autoimmune diseases |
| BRPI0401830A (pt) | 2004-05-25 | 2006-01-17 | Bentonit Uniao Nordeste Sa | Processo de produção de pós granulados secos |
| JP5399900B2 (ja) * | 2006-06-30 | 2014-01-29 | メルク・シャープ・アンド・ドーム・コーポレーション | Ｉｇｆｂｐ２インヒビター |
| WO2008073660A1 (en) | 2006-11-09 | 2008-06-19 | University Of Washington | Molecules and methods for treatment and detection of cancer |
| US9353415B2 (en) * | 2006-12-19 | 2016-05-31 | Thomson Reuters (Scientific) Llc | Methods for functional analysis of high-throughput experimental data and gene groups identified therefrom |
| JP2010517582A (ja) | 2007-02-12 | 2010-05-27 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 結腸癌の早期検出および予後診断の方法 |
| SI2472264T1 (sl) * | 2007-02-27 | 2016-06-30 | SentoClone International AB Karolinska Institute Science Park | Multipleksna detekcija tumorskih celic z uporabo plošč vezavnih sredstev na zunajcelične markerje |
| WO2008116178A2 (en) * | 2007-03-21 | 2008-09-25 | Vanderbilt University | Systems and methods for diagnosis and prognosis of colorectal cancer |
| WO2008138522A1 (en) * | 2007-05-10 | 2008-11-20 | Roche Diagnostics Gmbh | Use of timp-1 as a marker for colorectal cancer |
| EP2145021A2 (en) * | 2007-05-17 | 2010-01-20 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators |
| EP2171470A2 (en) * | 2007-06-04 | 2010-04-07 | Diagnoplex | Biomarker combinations for colorectal cancer |
| US20090017463A1 (en) * | 2007-07-10 | 2009-01-15 | Vanderbilt University | Methods for predicting prostate cancer recurrence |
| EP2271775A4 (en) * | 2008-04-08 | 2011-09-07 | Nuclea Biomarkers Llc | BIOMARKERGROUP FOR PREDICTING THE REPRESENTATION OF COLORECTAL CARCINOMA |
| US20100111969A1 (en) * | 2008-10-31 | 2010-05-06 | Apogenix Gmbh | Il-4 receptor and il-13 as prognostic markers for colon and pancreas tumors |
| US20100173024A1 (en) * | 2008-12-01 | 2010-07-08 | LifeSpan Extension, LLC | Methods and compositions for altering health, wellbeing, and lifespan |
| EP2370813A4 (en) * | 2008-12-04 | 2012-05-23 | Univ California | MATERIALS AND METHODS FOR DIAGNOSIS AND PRESENTATION OF PROSTATE CANCER |
| US9354233B2 (en) * | 2009-02-20 | 2016-05-31 | The Regents Of The University Of California | A+ biomarker assays |
| US20110177525A1 (en) * | 2010-01-19 | 2011-07-21 | Predictive Biosciences, Inc. | Antibodies and methods of diagnosing diseases |
| IN2013CN01129A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 2010-07-14 | 2015-07-31 | Commw Scient Ind Res Org |
-
2011
- 2011-07-14 IN IN1129CHN2013 patent/IN2013CN01129A/en unknown
- 2011-07-14 JP JP2013518909A patent/JP6061344B2/ja active Active
- 2011-07-14 EP EP14178981.8A patent/EP2829881B1/en active Active
- 2011-07-14 DK DK14178981.8T patent/DK2829881T3/en active
- 2011-07-14 BR BR112013000745-1A patent/BR112013000745B1/pt not_active IP Right Cessation
- 2011-07-14 PT PT141789818T patent/PT2829881T/pt unknown
- 2011-07-14 AU AU2011279555A patent/AU2011279555B2/en active Active
- 2011-07-14 WO PCT/AU2011/000895 patent/WO2012006681A1/en active Application Filing
- 2011-07-14 CN CN201180034158.5A patent/CN103140760B/zh active Active
- 2011-07-14 US US13/809,785 patent/US20130345322A1/en not_active Abandoned
- 2011-07-14 ES ES14178981.8T patent/ES2653646T3/es active Active
- 2011-07-14 EP EP11806149.8A patent/EP2593795A4/en not_active Withdrawn
- 2011-07-14 RU RU2013103995/15A patent/RU2013103995A/ru not_active Application Discontinuation
- 2011-07-14 NO NO14178981A patent/NO2829881T3/no unknown
- 2011-07-14 CN CN201511009181.5A patent/CN105755112B/zh active Active
-
2017
- 2017-03-28 US US15/471,147 patent/US10877039B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN105755112A (zh) | 2016-07-13 |
| PT2829881T (pt) | 2017-11-29 |
| RU2013103995A (ru) | 2014-08-20 |
| BR112013000745A2 (pt) | 2016-05-24 |
| BR112013000745B1 (pt) | 2021-02-02 |
| DK2829881T3 (en) | 2017-12-04 |
| US10877039B2 (en) | 2020-12-29 |
| EP2593795A4 (en) | 2014-01-22 |
| EP2593795A1 (en) | 2013-05-22 |
| JP2013533977A (ja) | 2013-08-29 |
| EP2829881A2 (en) | 2015-01-28 |
| EP2829881B1 (en) | 2017-08-23 |
| ES2653646T3 (es) | 2018-02-08 |
| WO2012006681A1 (en) | 2012-01-19 |
| CN105755112B (zh) | 2019-06-07 |
| CN103140760B (zh) | 2016-01-27 |
| CN103140760A (zh) | 2013-06-05 |
| US20130345322A1 (en) | 2013-12-26 |
| IN2013CN01129A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2015-07-31 |
| AU2011279555B2 (en) | 2016-10-20 |
| US20170205414A1 (en) | 2017-07-20 |
| AU2011279555A1 (en) | 2013-01-31 |
| NO2829881T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2018-01-20 |
| EP2829881A3 (en) | 2015-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6061344B2 (ja) | 大腸癌の診断 | |
| AU2009240781B2 (en) | An assay to detect a gynecological condition | |
| JP2011523049A (ja) | 頭頚部癌の同定、モニタリングおよび治療のためのバイオマーカー | |
| EP4063522A1 (en) | Composition for predicting response to standard preoperative chemoradiation therapy and prognosis following treatment, and method and composition for predicting patients with very unsatisfactory prognoses following standard therapy | |
| US20230142920A1 (en) | Kits and methods for detecting markers | |
| CN113234830B (zh) | 用于肺癌诊断的产品及用途 | |
| CN115087869A (zh) | 肺癌诊断用多种生物标志物及其用途 | |
| CN109975549B (zh) | 肿瘤来源IgG在胰腺癌诊断或预后中的用途 | |
| US20250035631A1 (en) | Method of detecting adenoma | |
| WO2025157220A1 (zh) | 结直肠癌标志物及其应用 | |
| CN113981098A (zh) | 用于肝癌诊断以及肝癌预后预测的生物标志物 | |
| CN113444796A (zh) | 与肺癌相关的生物标志物及其在诊断癌症中的应用 | |
| US20240393336A1 (en) | Biomarkers for colorectal cancer | |
| CN114107504A (zh) | 用于检测肺癌及肺癌预后的生物标志物 | |
| US20240118282A1 (en) | Kits and methods for detecting markers and determining the presence or risk of cancer | |
| CN114015778A (zh) | 预测肺癌的生物标志物组 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140711 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140730 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20150130 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150217 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150513 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150817 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160126 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160426 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160624 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160726 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20160727 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20161004 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161018 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20161115 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20161208 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6061344 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |